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Abstract: Adverse thromboembolic events following administration of the anti-fibrinolytic agent
tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical
course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose
chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk
neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after
systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved
hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association.
Keywords: pediatric hematopoietic stem cell transplantation; embryonal tumor; transplant-related
complication; fibrinolysis inhibitor; thrombotic event
1. Introduction
Hepatic sinusoidal obstruction syndrome (SOS), previously known as hepatic veno-occlusive
disease, is a non-hematological complication of the chemo- or radiotherapy-based conditioning
regimens used in the allogeneic and, less frequently, autologous hematopoietic stem cell transplantation
(HSCT) setting [1]. The primary event causing this potentially life-threatening syndrome affects the
sinusoidal endothelial cells surrounding the central vein in the hepatic acini [1,2]. The complex cascades
triggering injury and sinusoidal endothelial cell activation in the liver include the glutathione-based
detoxification of chemotherapeutics and their metabolites, cytokine release by tissues damaged through
the conditioning regimen and hemostatic system activation [2]. Occlusion of the venular lumen,
post-sinusoidal hypertension eventually causing retrograde portal venous flow and hepatocellular
necrosis lead, untreated in severe cases, to liver failure, hepatorenal syndrome and multisystem organ
failure, and ultimately to death in ≥80% of cases [1]. First described in 1979 [3,4], SOS is diagnosed in
HSCT recipients by applying the European Society for Blood and Marrow Transplantation (EBMT)
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diagnostic criteria for adults [1] or Baltimore criteria [5]/(modified) Seattle criteria [6], which include
the day of onset after HSCT, hyperbilirubinemia ≥2 mg/dL (~34 µmol/L), tender hepatomegaly
and/or unexplained weight gain greater than 5% over baseline by fluid retention in the third space.
The EBMT diagnostic criteria for children additionally include weight gain and rising bilirubin over
3 consecutive days, respectively, as well as unexplained consumptive and transfusion-refractory
thrombocytopenia [7]. The different diagnostic criteria are shown side by side in Table 1.
Table 1. Different diagnostic criteria for SOS in adults and children.
Baltimore Criteria for Adults, 1987 [5] Modified Seattle Criteria for Adults, 1984 [6] EMBT Criteria for Children, 2018 [7]
Bilirubin serum level >2 mg/dL and at




• Weight gain >5% from baseline
Two of following occurring within 21 days after
HSCT:
• Hepatomegaly or right upper
quadrant pain
• Bilirubin serum level >2 mg/dL
• Unexplained weight gain >2%
from baseline
No limitation for time of SOS onset





• Otherwise unexplained weight
gain on 3 consecutive days
despite the use of diuretics or a




• Rising bilirubin from a baseline
value on 3 consecutive days or
≥2 mg/dL within 72 h
EBMT: European Society for Blood and Marrow Transplantation; HSCT: hematopoietic stem cell transplantation;
SOS: sinusoidal obstruction syndrome.
2. Results
The 56-month-old child was treated according to the NB2004 High-Risk Trial protocol for
International Neuroblastoma Risk Group (INRG) stage M neuroblastoma without MYCN amplification,
with six cycles of antineoplastic polychemotherapy followed by complete resection of the primary
tumor arising from the left adrenal gland. Complete remission was verified by magnetic resonance
imaging (MRI), iodine-123-metaiodobenzylguanidine scintigraphy and bone marrow aspiration before
consolidation treatment with high-dose chemotherapy (consisting of Bu/Mel) and autologous HSCT.
On day 14, macrohematuria mediated by a BK virus cystitis was diagnosed. On day 17, bleeding caused
a drop in hemoglobin level from 10 to 7 g/dL and, ultimately, grade IV vesical tamponade developed
despite intensive intravenous hydration with >5000 L/qm2 body surface. To halt extensive blood loss
from multiple mucosal lesions in the urinary bladder that were too diffuse to be treated by vascular
obliteration, 15 mg tranexamic acid (TA)/kg body weight was systemically administered in three
single doses at 12-h intervals (Figure 1a). According to Corbacioglu S et al. [7], the EBMT criteria
for diagnosing SOS in children were fulfilled ~48 h later, namely tender hepatomegaly, weight gain
>5% above baseline due to ascites and rising bilirubin on 3 consecutive days (Figure 1a). In addition,
thrombocytopenia with rapid platelet consumption and an increase in D-dimers above 20.00 mg/L
were observed (Figure 1a). Bilirubin levels peaked at only 1.63 mg/dl (~27.72 µM) (Figure 1a).
Defibrotide treatment was immediately initiated and administered for a total of 21 days at 6.25 mg/kg
body weight in 6-h intervals (Figure 1a). According to EBMT criteria for grading SOS severity in
children [7], the patient developed a very severe SOS due to the rapid bilirubin kinetics and prolonged
refractory thrombocytopenia. The patient fully recovered by day 30.
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Figure 1. Schematic diagram illustrating medical interventions, clinical signs and laboratory 
parameters of a 4-8/12-year-old INRG stage M neuroblastoma patient (a) and a 1-10/12-year-old INRG 
stage M neuroblastoma patient (b) receiving myeloablative chemotherapy and autologous stem cell 
rescue. Arrow, therapy application; bold grey line, treatment interval; red line, D-dimer values 
(mg/L); black line, total bilirubin level (mmol/L); green line, body weight (kg); blue dots, thrombocyte 
transfusions. CD: cluster of differentiation; G-CSF: granulocyte colony-stimulating factor; INRG: 
International Neuroblastoma Risk Group; PBSCT: peripheral blood stem cell transplantation. 
Figure 1. Schematic diagram illustrating medical interventions, clinical signs and laboratory parameters
of a 4-8/12-year-old INRG stage M neuroblastoma patient (a) and a 1-10/12-year-old INRG stage M
neuroblastoma patient (b) receiving myeloablative chemotherapy and autologous stem cell rescue.
Arrow, therapy application; bold grey line, treatment interval; red line, D-dimer values (mg/L); black line,
total bilirubin level (mmol/L); green line, body weight (kg); blue dots, thrombocyte transfusions.
CD: cluster of differentiation; G-CSF: gr nulocyte colony-stimulating factor; INRG: International
Neuroblastoma Risk Grou ; PBSCT: peripheral blood stem c ll transplantation.
The 22-month-old child was treated according to the NB Registry 2016 for INRG stage M
neuroblastoma with MYCN amplification. After induction treatment and complete resection of
the primary tumor, consolidation treatment followed, with high-dose chemotherapy (Bu/Mel) and
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autologous HSCT. A total of 15 mg TA/kg body weight was systemically administered in two boluses
within 2 h on day 20 in response to a hemodynamically relevant hemorrhage from the insertion channel
after central venous catheter exchange. Within 24 h, the patient developed right upper quadrant pain,
weight gain >5% above baseline, consumptive thrombocytopenia and showed rising serum bilirubin
on 3 consecutive days, reaching >2 mg/dL after 96 h. Thus, the EBMT diagnostic criteria for children
were fulfilled on day 21, and defibrotide treatment was initiated (Figure 1b). According to EBMT
criteria for grading SOS severity in children [7], the patient developed a very severe SOS due to the
rapid bilirubin kinetics and greater than eight-fold increased transaminases combined with the need
for replacement of coagulation factors. The patient recovered only after intensified and prolonged
continuation of defibrotide by day 48 (Figure 1b).
The children were treated at a single institution that conducts approximately 50 allogeneic and
autologous transplantations per year. To date, 15 children with neuroblastoma have received an
autologous HSCT after Bu/Mel conditioning at our department since June 2016. The two patients
described in this case report developed SOS in close temporal context to TA administration, and one
patient developed a grade 4 SOS without prior treatment with TA. The remaining 12 patients did not
develop SOS and none of them received TA during the period around autologous HSCT.
3. Conclusions
TA competitively blocks the lysine-binding sites of plasminogen, plasmin and tissue plasminogen
activator [8] to reversibly impede fibrinolysis and blood clot degradation. TA is mainly used to prevent
or treat excessive blood loss after liver transplantation [9] and multiple trauma [10]. Several risk factors
for SOS development are present in both patients, namely, both were diagnosed with neuroblastoma
and both received myeloablative conditioning containing busulfan before autologous HSCT. We suggest
that the temporal relationship between the use of TA and SOS onset, rather, indicates a causal and not
coincidental connection, although additional evidence is needed to prove TA treatment as a risk factor
for SOS. Animal models of SOS provide a suitable platform for further studies [11,12]. Thus, the systemic
application of TA to prevent bleeding complications early after myeloablative therapy should be
carefully considered due to increasing evidence for a potentially additive role in SOS development [13],
especially in patients with pre-existing high-risk features for hepatic SOS. Tandem myeloablative
consolidation therapy has been shown to improve survival probability in patients with high-risk
neuroblastoma [14], emphasizing the importance of minimizing transplant-related morbidity.
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